UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments

Area of Science:

• Public Health and Epidemiology
• Vaccinology and Infectious Disease Research

Background:

• The 2013-2016 Ebola outbreak in West Africa highlighted the need for proactive epidemic preparedness.
• An expert panel was convened by the UK Prime Minister to identify high-risk pathogens.
• This initiative aimed to prioritize national investment in emerging disease vaccine research and development.

Purpose of the Study:

• To detail the methodology behind the UK's pathogen priority list creation.
• To compare the UK list with international priority pathogen lists (WHO, NIAID).
• To review the clinical development status of vaccines for identified priority diseases.

Main Methods:

• Convening an expert panel to identify pathogens with epidemic potential.
• Comparative analysis of the UK priority list against global benchmarks.
• Review of current vaccine research and clinical trial progress for selected pathogens.

Main Results:

• Identification of 13 priority pathogens, influencing UK R&D funding allocation.
• Significant technical advancements in vaccine development for several priority diseases.
• Comparison revealed alignment with, and distinct priorities from, WHO and NIAID lists.

Conclusions:

• The UK pathogen priority list provides a framework for targeted vaccine R&D investment.
• Substantial progress has been made in vaccine technology for priority pathogens.
• Sustained funding for clinical trials and manufacturing readiness is essential for vaccine availability during inter-epidemic periods.